RXDX / Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

Does Prometheus Biosciences, Inc. (RXDX) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal

Prometheus Biosciences, Inc. (RXDX) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.92. This com more_horizontal

Merck plans to acquire Prometheus for $10.8 billion in an all-cash deal. The deal will add Prometheus' lead candidate, immunology drug PRA023, to Merc more_horizontal

Merck (known as MSD outside the United States and Canada) and Prometheus Biosciences recently announced that the companies have entered into a definit more_horizontal

Prometheus Biosciences, Inc. (RXDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revision more_horizontal

Prometheus' lead therapy treats ulcerative colitis and a variety of autoimmune disorders. Merck is looking to supplement its immunology portfolio. more_horizontal

Prometheus Biosciences Inc (NASDAQ: RXDX) opened about 70% up on Monday after Merck & Co Inc (NYSE: MRK) said it will buy the biotechnology company fo more_horizontal

Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' more_horizontal